Eric Coldwell

Could you just tell us what that multiyear capture was what the actual nature of that tax item is?

just want to make sure that, that is 100% Cardinal-specific, how you're going to market

Are you thinking at all about the potential for many more of these biologics to actually start to see R&D and advancement of biosimilars based on some of the things happening in D.C.?

do you have Nairobi protocol protections in place today for any of your products

is there not also a med-surg opportunity, particularly in this segment? And if so, could you talk about that

I just want to confirm that profit in the segment would have more than doubled, it looks like, if not for the unexpected increase

You also do cell and gene therapy and other specialty shipments unrelated to clinical trials, so I'm wondering how those are faring

you're half of one of the leading manufacturers' distribution volume. Is that a similar share across the entire market

you provide in your appendix the NHP utilization for 2024, and you gave an update for 2025 which was a pretty notable growth

I do not know, dichotomy in the outlook and results here between RMS and DSA. Hoping you can just walk us through this and help clear it up

Can you possibly give us a sense on how much you would expect to fall to the bottom line?

I'm curious if you have any updated thoughts on what that might lead to

where would you be framing DSA to start the year?

was it just that there was particularly high margin on that amount, like less work, but final payouts?

Where does Charles River -- where do you feel you stand out the most, where you're truly an industry thought leader, have maybe higher share versus competitors?

I'd love you to put that in perspective and maybe talk through what you see happening in the government in terms of various fraud, waste and abuse initiatives

Is it possible to size if there's some way to frame these investments relative to last year or relative to original expectations?

If we add $250 million back to reported awards, as if pass-throughs were normal, that would get us to about a 1.15 book-to-bill. Is that logic consistent

I was hoping to dig into the latest acquisition, Cedar Gate

the impact on guidance from FX

Would you care to quantify that cancellation?

On the central lab COVID comp, in Q1, are there additional COVID comps throughout 2025 that we should be aware of?

is it a 1% enterprise revenue kind of impact, 2%, something less than that?

what kind of a revenue slowdown are you seeing in 3PL, i.e., could we get a better sense on the growth forecast